
Kodiak Sciences Inc. (NASDAQ:KOD – Free Report) – Equities researchers at HC Wainwright cut their FY2026 EPS estimates for Kodiak Sciences in a report released on Monday, November 16th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($3.91) per share for the year, down from their prior estimate of ($3.75). HC Wainwright currently has a “Buy” rating and a $126.00 target price on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for Kodiak Sciences’ FY2027 earnings at ($3.52) EPS, FY2028 earnings at ($1.27) EPS, FY2029 earnings at $1.76 EPS and FY2030 earnings at $6.09 EPS.
Other equities analysts have also issued research reports about the company. The Goldman Sachs Group initiated coverage on Kodiak Sciences in a research note on Wednesday, September 30th. They issued a “neutral” rating and a $103.00 price objective on the stock. Lifesci Capital increased their target price on Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a report on Monday, September 28th. JPMorgan Chase & Co. raised their target price on Kodiak Sciences from $124.00 to $128.00 and gave the company an “overweight” rating in a research note on Thursday. UBS Group lifted their price target on Kodiak Sciences from $120.00 to $150.00 and gave the company a “buy” rating in a report on Friday, November 13th. Finally, Wall Street Zen upgraded shares of Kodiak Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.86.
Kodiak Sciences Price Performance
KOD stock opened at $98.02 on Wednesday. The business has a fifty day moving average price of $81.85 and a 200 day moving average price of $47.23. Kodiak Sciences has a fifty-two week low of $19.25 and a fifty-two week high of $112.79. The stock has a market capitalization of $6.41 billion, a price-to-earnings ratio of -24.02 and a beta of 2.02.
Kodiak Sciences (NASDAQ:KOD – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.01.
Institutional Investors Weigh In On Kodiak Sciences
Several institutional investors have recently modified their holdings of KOD. Ghisallo Capital Management LLC lifted its holdings in Kodiak Sciences by 33.3% in the third quarter. Ghisallo Capital Management LLC now owns 200,000 shares of the company’s stock valued at $18,960,000 after buying an additional 50,000 shares during the period. Baker BROS. Advisors LP boosted its stake in Kodiak Sciences by 9.7% in the third quarter. Baker BROS. Advisors LP now owns 21,860,941 shares of the company’s stock valued at $2,072,417,000 after acquiring an additional 1,941,755 shares during the last quarter. Soleus Capital Management L.P. acquired a new stake in Kodiak Sciences during the 3rd quarter worth $27,204,000. Bellevue Group AG acquired a new stake in Kodiak Sciences during the 3rd quarter worth $43,648,000. Finally, Cetera Investment Advisers acquired a new stake in Kodiak Sciences during the 3rd quarter worth $231,000. Institutional investors and hedge funds own 89.06% of the company’s stock.
Insiders Place Their Bets
In other Kodiak Sciences news, Director Bros. Advisors Lp Baker bought 86,432 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were bought at an average cost of $98.51 per share, for a total transaction of $8,514,416.32. Following the transaction, the director owned 20,424,859 shares in the company, valued at approximately $2,012,052,860.09. This trade represents a 0.42% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders bought 2,188,845 shares of company stock worth $181,326,862. Insiders own 44.40% of the company’s stock.
Kodiak Sciences Company Profile
Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.
Featured Articles
- Five stocks we like better than Kodiak Sciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
